Kevin Outterson is the founding Executive Director at CARB-X, the world’s leading public-private partnership that accelerates the early-stage development of innovative products to prevent, diagnose and treat bacterial infections.
CARB-X has supported more than 120 R&D projects worldwide, and more than two dozen have reached or surpassed first-in-human clinical trials, including three products already on the market. In 2020, the Global Health Technologies Coalition awarded CARB-X the Innovating for Impact Partnership Award. CARB-X funders include the governments of the United States, Germany, the United Kingdom, Italy, Canada and Japan, plus the European Commission, Wellcome, the Novo Nordisk Foundation and the Gates Foundation.